BR112017012504A2 - derivados de piperidina como inibidores de hdac1/2 - Google Patents

derivados de piperidina como inibidores de hdac1/2

Info

Publication number
BR112017012504A2
BR112017012504A2 BR112017012504-8A BR112017012504A BR112017012504A2 BR 112017012504 A2 BR112017012504 A2 BR 112017012504A2 BR 112017012504 A BR112017012504 A BR 112017012504A BR 112017012504 A2 BR112017012504 A2 BR 112017012504A2
Authority
BR
Brazil
Prior art keywords
hdac1
inhibitors
piperidine derivatives
compounds
methods
Prior art date
Application number
BR112017012504-8A
Other languages
English (en)
Inventor
H. Van Duzer John
Mazitschek Ralph
Original Assignee
Acetylon Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acetylon Pharmaceuticals, Inc. filed Critical Acetylon Pharmaceuticals, Inc.
Publication of BR112017012504A2 publication Critical patent/BR112017012504A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

são fornecidos no presente documento compostos, composições farmacêuticas que compreendem tais compostos e métodos de uso de tais compostos para tratar doenças ou distúrbios associados à atividade de hdac1 e/ou hdac2.
BR112017012504-8A 2014-12-12 2015-12-11 derivados de piperidina como inibidores de hdac1/2 BR112017012504A2 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462091221P 2014-12-12 2014-12-12
US62/091,221 2014-12-12
US201562238931P 2015-10-08 2015-10-08
US62/238,931 2015-10-08
PCT/US2015/065289 WO2016094824A1 (en) 2014-12-12 2015-12-11 Piperidine derivatives as hdac1/2 inhibitors

Publications (1)

Publication Number Publication Date
BR112017012504A2 true BR112017012504A2 (pt) 2018-01-09

Family

ID=56108272

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017012504-8A BR112017012504A2 (pt) 2014-12-12 2015-12-11 derivados de piperidina como inibidores de hdac1/2

Country Status (17)

Country Link
US (6) US9790180B2 (pt)
EP (2) EP3725787B1 (pt)
JP (1) JP6693957B2 (pt)
KR (1) KR20170095964A (pt)
CN (1) CN107835810A (pt)
AU (2) AU2015360270B9 (pt)
BR (1) BR112017012504A2 (pt)
CA (1) CA2970500C (pt)
CL (1) CL2017001511A1 (pt)
EA (1) EA035120B1 (pt)
ES (1) ES2816641T3 (pt)
HK (1) HK1251566A1 (pt)
IL (1) IL252828A0 (pt)
MX (2) MX2017007623A (pt)
PH (1) PH12017501095A1 (pt)
SG (1) SG11201704759QA (pt)
WO (1) WO2016094824A1 (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
EP3054952B1 (en) 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
JP6535670B2 (ja) 2013-12-03 2019-06-26 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
MX2017007623A (es) * 2014-12-12 2018-09-26 Regenacy Pharmaceuticals Llc Derivados de piperidina como inhibidores de hdac1/2.
PT3231793T (pt) 2014-12-12 2020-05-06 Japan Tobacco Inc Compostos de di-hidropirimidina-2-ona e utilizações médicas dos mesmos
US10464906B2 (en) 2015-06-08 2019-11-05 Acetylon Pharmaceuticals, Inc. Crystalline forms of a histone deacetylase inhibitor
ES2769255T3 (es) 2015-06-08 2020-06-25 Acetylon Pharmaceuticals Inc Métodos para fabricar inhibidores de la proteína desacetilasa
US11324744B2 (en) 2016-08-08 2022-05-10 Acetylon Pharmaceuticals Inc. Methods of use and pharmaceutical combinations of histone deacetylase inhibitors and CD20 inhibitory antibodies
KR20200126973A (ko) 2018-02-28 2020-11-09 니뽄 다바코 산교 가부시키가이샤 4-메틸디히드로피리미디논 화합물 및 그의 의약 용도
CN110372572A (zh) * 2019-08-23 2019-10-25 苏州汉德创宏生化科技有限公司 一种4,4-二氟哌啶-1-甲酰氯的合成方法
WO2024030659A1 (en) 2022-08-05 2024-02-08 Tango Therapeutics, Inc. An hdac inhibitor for treating cancer with a modified stk11 activity or expression

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1485099B1 (en) * 2002-03-13 2010-07-07 Janssen Pharmaceutica N.V. Inhibitors of histone deacetylase
NZ534830A (en) * 2002-03-13 2005-08-26 Janssen Pharmaceutica Nv Compounds with histone deacetylase HDAC inhibiting activity and oral bioavailability useful for treating proliferative diseases
EP1663953A1 (en) * 2003-09-24 2006-06-07 Methylgene, Inc. Inhibitors of histone deacetylase
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
EP2007720B1 (en) 2006-04-07 2013-12-25 MethylGene Inc. Benzamide derivatives as inhibitors of histone deacetylase
CA2649861A1 (en) 2006-04-26 2007-11-08 Merck & Co., Inc. Disubstituted aniline compounds
US8119652B2 (en) * 2006-05-18 2012-02-21 Merck Sharp & Dohme Corp. Aryl-fused spirocyclic compounds
US20080175814A1 (en) * 2006-10-12 2008-07-24 Supergen, Inc. Quinoline derivatives for modulating dna methylation
JP2010120852A (ja) 2007-03-09 2010-06-03 Daiichi Sankyo Co Ltd 新規なジアミド誘導体
JP2010539104A (ja) 2007-09-14 2010-12-16 メチルジーン インコーポレイテッド ヒストンデアセチラーゼｈｄａｃ１、ｈｄａｃ２および／またはｈｄａｃ３の選択的阻害剤ならびに微小管安定剤による癌の組合せ治療
US7790746B2 (en) 2007-10-12 2010-09-07 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
US7939546B2 (en) 2007-10-12 2011-05-10 Supergen, Inc. Quinoline derivatives for modulating DNA methylation
HUE030679T2 (en) 2010-01-22 2017-05-29 Acetylon Pharmaceuticals Inc Reverse amide compounds as protein deacetylase inhibitors and methods of use
WO2012018499A2 (en) 2010-08-05 2012-02-09 Acetylon Pharmaceuticals Specific regulation of cytokine levels by hdac6 inhibitors
CN107011270A (zh) 2010-11-16 2017-08-04 阿塞蒂隆制药公司 作为蛋白质去乙酰化酶抑制剂的嘧啶羟基酰胺化合物和其使用方法
US9249087B2 (en) 2011-02-01 2016-02-02 The Board Of Trustees Of The University Of Illinois HDAC inhibitors and therapeutic methods using the same
CN102775356B (zh) * 2011-05-13 2015-07-22 江苏恒谊药业有限公司 4-氨基喹唑啉衍生物及其应用
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
EP2839037B1 (en) 2012-04-19 2018-12-26 Acetylon Pharmaceuticals, Inc. Biomarkers to identify patients that will respond to treatment and treating such patients
US9145412B2 (en) 2012-11-02 2015-09-29 Acetylon Pharmaceuticals, Inc. Selective HDAC1 and HDAC2 inhibitors
US9096549B2 (en) 2013-02-01 2015-08-04 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
US9139583B2 (en) 2013-02-01 2015-09-22 Acetylon Pharmaceuticals, Inc. Selective HDAC3 inhibitors
WO2014197471A1 (en) 2013-06-03 2014-12-11 Acetylon Pharmaceuticals, Inc. Histone deacetylase ( hdac) biomarkers in multiple myeloma
EP3054952B1 (en) 2013-10-08 2022-10-26 Acetylon Pharmaceuticals, Inc. Combinations of histone deacetylase 6 inhibitors and the her2 inhibitor lapatinib for use in the treatment of breast cancer
WO2015054197A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Hdac inhibitors, alone or in combination with btk inhibitors, for treating non-hodgkin's lymphoma
JP6584391B2 (ja) 2013-10-10 2019-10-02 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 非ホジキンリンパ腫を治療するための、ｈｄａｃ阻害剤単独またはｐｉ３ｋ阻害剤との組み合わせ
WO2015054474A1 (en) 2013-10-10 2015-04-16 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as histone deacetylase inhibitors
CN105722507A (zh) 2013-10-11 2016-06-29 埃斯泰隆制药公司 组蛋白脱乙酰酶抑制剂与免疫调节药物的组合
JP6535670B2 (ja) 2013-12-03 2019-06-26 アセチロン ファーマシューティカルズ インコーポレイテッドＡｃｅｔｙｌｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． ヒストンデアセチラーゼ阻害剤と免疫調節薬の組合せ
JP7017309B2 (ja) 2013-12-20 2022-02-08 アセチロン ファーマシューティカルズ インコーポレイテッド 多発性骨髄腫におけるヒストン脱アセチル化酵素６（ｈｄａｃ６）バイオマーカー
US9464073B2 (en) 2014-02-26 2016-10-11 Acetylon Pharmaceuticals, Inc. Pyrimidine hydroxy amide compounds as HDAC6 selective inhibitors
KR20170044097A (ko) 2014-07-07 2017-04-24 에이스틸론 파마수티컬스 인코포레이티드 히스톤 탈아세틸화효소 저해제에 의한 백혈병의 치료
US20160137630A1 (en) 2014-10-08 2016-05-19 Acetylon Pharmaceuticals, Inc. Induction of gata2 by hdac1 and hdac2 inhibitors
MX2017007623A (es) * 2014-12-12 2018-09-26 Regenacy Pharmaceuticals Llc Derivados de piperidina como inhibidores de hdac1/2.

Also Published As

Publication number Publication date
HK1251566A1 (zh) 2019-02-01
EP3292113B1 (en) 2020-07-08
US20190359569A1 (en) 2019-11-28
EP3725787B1 (en) 2023-11-29
AU2015360270A1 (en) 2017-07-13
US10358421B2 (en) 2019-07-23
AU2015360270B9 (en) 2019-12-05
EP3725787A1 (en) 2020-10-21
JP6693957B2 (ja) 2020-05-13
US10239837B2 (en) 2019-03-26
IL252828A0 (en) 2017-08-31
AU2015360270B2 (en) 2019-11-28
CA2970500A1 (en) 2016-06-16
US20210179559A1 (en) 2021-06-17
JP2018502841A (ja) 2018-02-01
ES2816641T3 (es) 2021-04-05
EP3292113A1 (en) 2018-03-14
EA201791259A1 (ru) 2017-11-30
US9790180B2 (en) 2017-10-17
KR20170095964A (ko) 2017-08-23
SG11201704759QA (en) 2017-07-28
EP3292113A4 (en) 2018-07-04
US20180022702A1 (en) 2018-01-25
US20170369441A1 (en) 2017-12-28
MX2020002487A (es) 2020-07-13
WO2016094824A1 (en) 2016-06-16
PH12017501095A1 (en) 2017-10-18
CL2017001511A1 (es) 2018-02-16
CA2970500C (en) 2023-08-29
AU2020200846A1 (en) 2020-02-27
US11702389B2 (en) 2023-07-18
US20160168093A1 (en) 2016-06-16
MX2017007623A (es) 2018-09-26
US10968180B2 (en) 2021-04-06
EA035120B1 (ru) 2020-04-29
US20230348389A1 (en) 2023-11-02
CN107835810A (zh) 2018-03-23

Similar Documents

Publication Publication Date Title
BR112017012504A2 (pt) derivados de piperidina como inibidores de hdac1/2
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CO2017011851A2 (es) Compuestos novedosos
EA201990665A1 (ru) Регуляторы hpk1 на основе производных пиразолопиридина и их применение для лечения рака
CL2016002072A1 (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CO2017004525A2 (es) Dihidropirrolopiridinas inhibidoras de ror-gamma
CL2016001895A1 (es) Compuestos
BR112019001607A2 (pt) inibidores macrocíclicos de quinases
BR112017003312A2 (pt) compostos de indazol como inibidores de fgfr quinase, preparação e uso dos mesmos
BR112016025048A2 (pt) compostos e composições como agonistas do receptor tipo toll7
NI201300073A (es) Compuestos y composiciones como inhibidores de la trk
SA518400356B1 (ar) مثبطات الأرجيناز واستخداماتها العلاجية
BR112018016968A2 (pt) derivados de carboxamida úteis como inibidores de rsk
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX2022007436A (es) Inhibidores de la autotaxina y sus usos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
BR112017026535A2 (pt) composto de fórmula estrutural i, enantiômero isolado, composição farmacêutica, método para inibir atividade do transportador de monocarboxilato mct4, método para inibir seletivamente atividade do transportador de monocarboxilato mct4, método para tratar um distúrbio mediado por transportador de monocarboxilato mct4 e uso de um composto
MX370270B (es) Inhibidores de glucosilceramida sintasa para el tratamiento de enfermedades.
BR112018014590A2 (pt) formulações/composições compreendendo um inibidor de btk
BR112017018198A2 (pt) inibição da atividade de olig2
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
BR112017022032A2 (pt) métodos para tratamento de transtornos de armazenamento lisossômico
BR112017016388A2 (pt) cenicriviroc para o tratamento da fibrose
CR20170426A (es) Inhibidores de bace 1

Legal Events

Date Code Title Description
B65X Notification of requirement for priority examination of patent application
B65Y Grant of priority examination of the patent application (request complies with dec. 132/06 of 20061117)
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL